Tenhunen M - Search Results

1

Dosimetry of radionuclide therapy using radiophosphonated antisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data.

Kairemo KJ, Tenhunen M, Jekunen AP. Kairemo KJ, et al. Among authors: tenhunen m. Antisense Nucleic Acid Drug Dev. 1996 Fall;6(3):215-20. doi: 10.1089/oli.1.1996.6.215. Antisense Nucleic Acid Drug Dev. 1996. PMID: 8915506

2

Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates.

Kairemo KJ, Tenhunen M, Jekunen AP. Kairemo KJ, et al. Among authors: tenhunen m. Anticancer Drug Des. 1996 Sep;11(6):439-49. Anticancer Drug Des. 1996. PMID: 8836109

3

The effect of three dimensional activity distribution on the dose planning of radioimmunotherapy for patients with advanced intraperitoneal pseudomyxoma.

Laitinen JO, Kairemo KJ, Jekunen AP, Korppi-Tommola T, Tenhunen M. Laitinen JO, et al. Among authors: tenhunen m. Cancer. 1997 Dec 15;80(12 Suppl):2545-52. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2545::aid-cncr29>3.3.co;2-t. Cancer. 1997. PMID: 9406708

4

Gene therapy using antisense oligodeoxynucleotides labeled with Auger-emitting radionuclides.

Kairemo KJ, Tenhunen M, Jekunen AP. Kairemo KJ, et al. Among authors: tenhunen m. Cancer Gene Ther. 1998 Nov-Dec;5(6):408-12. Cancer Gene Ther. 1998. PMID: 9917096

5

The use of TL detectors in dosimetry of systemic radiation therapy.

Aschan AC, Toivonen MJ, Lampinen JS, Tenhunen M, Kairemo KJ, Korppi-Tommola ET, Jekunen AP, Sipilä P, Savolainen SE. Aschan AC, et al. Among authors: tenhunen m. Acta Oncol. 1999;38(2):189-96. doi: 10.1080/028418699431609. Acta Oncol. 1999. PMID: 10227440

6

Problems associated with oligonucleotide radiotherapy.

Kairemo KJ, Jekunen AP, Tenhunen M. Kairemo KJ, et al. Among authors: tenhunen m. J Nucl Med. 1999 Sep;40(9):1582. J Nucl Med. 1999. PMID: 10492382 Free article. No abstract available.

7

Dosimetry and optimization of in vivo targeting with radiolabeled antisense oligodeoxynucleotides: oligonucleotide radiotherapy.

Kairemo KJ, Jekunen AP, Tenhunen M. Kairemo KJ, et al. Among authors: tenhunen m. Methods Enzymol. 2000;314:506-24. doi: 10.1016/s0076-6879(99)14126-0. Methods Enzymol. 2000. PMID: 10565036 No abstract available.

8

Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.

Erselcan T, Kairemo KJ, Wiklund TA, Hernberg M, Blomqvist CP, Tenhunen M, Bergh J, Joensuu H. Erselcan T, et al. Among authors: tenhunen m. Br J Cancer. 2000 Feb;82(4):777-81. doi: 10.1054/bjoc.1999.0998. Br J Cancer. 2000. PMID: 10732745 Free PMC article. Clinical Trial.

9

Absorbed dose estimates for 131I-labelled monoclonal antibody therapy in patients with intraperitoneal pseudomyxoma.

Laitinen JO, Tenhunen M, Kairemo KJ. Laitinen JO, et al. Among authors: tenhunen m. Nucl Med Commun. 2000 Apr;21(4):355-60. doi: 10.1097/00006231-200004000-00010. Nucl Med Commun. 2000. PMID: 10845224

10

Scintigraphy in prediction of the salivary gland function after gland-sparing intensity modulated radiation therapy for head and neck cancer.

Tenhunen M, Collan J, Kouri M, Kangasmäki A, Heikkonen J, Kairemo K, Mäkitie A, Joensuu H, Saarilahti K. Tenhunen M, et al. Radiother Oncol. 2008 May;87(2):260-7. doi: 10.1016/j.radonc.2008.02.017. Epub 2008 Mar 7. Radiother Oncol. 2008. PMID: 18329118

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters